Analogic produces new ultrasound engine for supply to OEMs

Article

Plain vanilla vies with tailor-made versionsLongtime OEM supplier Analogic has begun producing a digital ultrasound engine for niche providers of ultrasound and other clinical services and products. OEMs add transducers,

Plain vanilla vies with tailor-made versions

Longtime OEM supplier Analogic has begun producing a digital ultrasound engine for niche providers of ultrasound and other clinical services and products. OEMs add transducers, application software, and other components to the engine to make an end-user product.

The AN2300 provides the features and image quality needed to support clinical applications such as cardiology, general radiology, or breast and small parts imaging. Key features include parallel beam processing; beam steering; spectral, color flow, or power Doppler; and line-interleaved duplex or triplex combination modes. The use of industry-standard PC platforms allows customers to take advantage of continuing increases in PC processing power.

Depending on configuration and the number of systems purchased, the AN2300 sells for between $23,000 and $30,000. Analogic began producing the system in January, just a little over a month after it was shown as a work-in-progress at the RSNA meeting.

Axel Wirth, manager of sales and marketing for the Peabody, MA, company's OEM ultrasound systems division, described the AN2300 as the key building block for an upper midrange ultrasound system. Customers can purchase the engine and configure it as they want, or they can buy the AN2300 customized to fit their individual needs. About half of Analogic's customers are expected to complete systems built around the AN2300 by themselves, said Wirth, who declined to provide sales projections for the engine.

"We're talking about specialty companies that work in some interventional or therapeutic clinical discipline," he said. "They are not necessarily the larger imaging companies. Some of them have no background in ultrasound imaging, but they need ultrasound as an enabling technology."

Many evolving interventional and therapeutic procedures rely heavily on ultrasound imaging as a driving technology, and developers may have limited experience using ultrasound. Other potential customers include those who perform limited clinical applications using ultrasound or who use the modality in a small geographic region, Wirth said. To them, it's more cost-effective to buy the engine and configure it themselves than to buy or develop a complete digital system with all the bells and whistles in place.

When the final system is assembled, OEMs submit the paperwork to regulatory agencies, such as the FDA, to allow sales and marketing. Although Analogic does not get directly involved in the clearance process, its staff supports the regulatory efforts of OEM customers, Wirth said.

Analogic is making the rounds at medical conferences and trade shows, hoping to drum up demand for the AN2300. Other marketing efforts include targeted mailings, magazine advertising, and direct customer contact. The primary customer group includes medical specialty companies, many of which sell diagnostic, therapeutic, and interventional devices. Analogic is not looking for an exclusive supply agreement with any one company.

"Since we provide the engine and customers finalize the end-user system, there's enough room for them to distinguish themselves from other companies that may buy the same engine from us," Wirth said.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.